Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nelli Dieterle"'
Autor:
Nelli Dieterle, S. Abdel-Rahman, Markus Albertsmeier, Lars H. Lindner, Michael Schmidt, Christiane Bruns, Martin K. Angele, Rolf-Dieter Issels, K. W. Jauch, Ulrich Mansmann, Peter Hohenberger, Niclas J. Prix
Publikováno v:
Annals of Surgery. 260:749-756
Retroperitoneal and abdominal soft-tissue sarcomas are rare tumors with a reported incidence of 2.7 cases per million.1 For localized abdominal and retroperitoneal tumors, surgical resection with gross negative margins remains the standard of care. A
Autor:
P.O. Aubele, S. Abdel-Rahman, Eric Kampmann, Gesa Schuebbe, Rolf-Dieter Issels, Ruediger P. Laubender, Lars H. Lindner, Nelli Dieterle
Publikováno v:
Annals of Oncology. 23:ix487
Introduction A phase III study showed that RHT combined with EIA (E = etoposide, I = ifosfamide and A= doxorubicin) is effective in HR-STS (Lancet Oncol, 2010). EIA + RHT significantly improved tumor response and prolonged local progression-free (LPF
Autor:
Nelli Dieterle, Frank Berger, Rolf D. Issels, Christoph Salat, S. Abdel-Rahman, Katharina Lechner
Publikováno v:
Annals of Oncology. 23:iv62
Introduction Gemcitabine (G) is the standard first-line treatment in patients with advanced pancreatic cancer (APC). Currently there is no standard second-line therapy for patients after G-failure. Cisplatin (Cis)-based chemotherapy has shown activit
Autor:
Jaap Verweij, Eric Kampmann, Lars H. Lindner, Clemens Martin Wendtner, R. Wessalowski, Thomas Kirchner, Ulrich Mansmann, Nelli Dieterle, Rolf D. Issels
Publikováno v:
Journal of Clinical Oncology. 30:10054-10054
10054 Background: A randomized phase III completed trial showed that RHT added to NAC was beneficial in terms of local progression-free (LPFS), and disease-free (DFS) survival. Overall survival (OS) was improved in patients (pts) who completed the pr
Autor:
Volker Heinemann, S. Ehrke, Ulrich Mansmann, Lars H. Lindner, R. D. Issels, B. Weber, Nelli Dieterle, S. Abdel-Rahman, K. Tschoep-Lechner, Christoph Salat, Christiane Bruns
Publikováno v:
Journal of Clinical Oncology. 29:e14524-e14524
e14524 Background: There is ongoing debate on the treatment benefit of gemcitabine (G) plus cisplatin (CIS) compared to G alone in firstline treatment of APC. However, from preclinical research it ...